<DOC>
	<DOCNO>NCT00313144</DOCNO>
	<brief_summary>The primary objective Phase 4 , open label , prospective U.S. surveillance study evaluate health outcome Alpha 1-Antitrypsin ( AAT ) -deficient subject initiate treatment ARALAST patient-related outcome ( PRO ) , i.e. , health-related quality life ( HRQoL ) , healthcare resource utilization ( HCRU ) , various laboratory analysis evaluate safety long-term administration ARALAST . Up 120 subject enrol assessed HRQoL HCRU baseline every 6-months thereafter , 2 year . A subset subject enrol blood draw portion study , also include assessment antibody ARALAST , chemistry panel . Subjects treat accord prescribing ( attend ) physician 's instruction base prescribe information give ARALAST package insert .</brief_summary>
	<brief_title>Aralast alpha1-proteinase Inhibitor Surveillance Study</brief_title>
	<detailed_description />
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Male female 18 year age old Diagnosis AAT deficiency associate emphysema Active prescription augmentation therapy ARALAST On service Coram ( speciality pharmacy provider ) Signed date informed consent Clinically significant medical ( COPD ) , psychiatric , cognitive illness , opinion Coram sponsor investigator , may compromise subject safety compliance ( end stage renal hepatic heart disease , metastatic cancer difficulty communicate telephone line ) Previous treatment ARALAST ( i.e . subject previously receive discontinue ARALAST augmentation therapy restart ARALAST exclude study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>